Thermo Fisher Scientific CD11a Monoclonal Antibody (87-6F9)

Applications

Tested Dilution

Publications

Immunohistochemistry (Frozen) (IHC (F))

Assay-dependent

-

Flow Cytometry (Flow)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG2b

Class

Monoclonal

Type

Antibody

Clone

87-6F9

Immunogen

Stimulated human leucocytes

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

100 µg/mL

Purification

purified

Storage buffer

PBS

Contains

0.02% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_1071156

Product Specific Information

87-6F9 Reacts with CD11a, a transmembrane molecule with 1145 amino acid residues and a MW of 180 kDa. CD11a is expressed on lymphocytes, granulocytes, monocytes and macrophages. Levels on memory T-cells tend to increase. CD11a plays a key role in mediating leukocyte adhesion to endothelium during inflammatory response through binding to ICAM 1 (CD54). Other ligands are ICAM-2 and ICAM-3. It is also involved in many other T-cell functions and immune phenomena. When paired with CD18, it forms the integrin alphaLbeta2 adhesion. 87-6F9 Potently blocks LFA-1 dependent homotypic cell aggregation and was typed in the IVth International Leucocyte Typing Workshop

Target Information

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin. CD11a is implicated in activation of LFA-1 complex. CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. Two transcript variants encoding different isoforms of CD11a have been found. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.